Thursday, January 31, 2019

Senate bill backed by patient groups eyes ‘annuity’ payments for pricey treatments

›
When healthcare wonks talk about alternative payment models for pricey treatments like gene and cell therapies, they’re usually referring t...

What’s BMS saying about its Celgene buy behind the scenes?

›
Bristol-Myers Squibb CEO Giovanni Caforio has friends on TV now. R&D chief Tom Lynch has done some of his CAR-T due diligence on YouTub...

Finding Your Transformation

›
The  recent post  on awakening your talent cited Courtney’s performance  on the talent show as a beautiful example of how we “become a di...

Botox Maker Argues Rival Drug Was Developed With Stolen Secrets

›
Allergan Plc  and partner  Medytox Inc.  are seeking to block U.S. imports of a new rival to the wrinkle-treatment Botox, claiming it was d...

SF Biochemist Sells ‘Gene-Editing Kit’ For The Masses

›
After scientists unlocked the secrets of the human genome in 2003, there was immediate concern about how that knowledge might be abused in ...

Sylentis’ dry eye drug misses primary goals in phase 3

›
A phase 3 trial of Sylentis’ dry eye disease candidate tivanisiran has  missed  (PDF) its primary endpoints. The PharmaMar subsidiary faile...

Allergan abandons women’s health sale plan as profit slumps

›
Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst...